Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Other Non-Current Liabilities (2022 - 2025)

Historic Other Non-Current Liabilities for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to $11.5 million.

  • Phathom Pharmaceuticals' Other Non-Current Liabilities rose 697.67% to $11.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.5 million, marking a year-over-year increase of 697.67%. This contributed to the annual value of $11.5 million for FY2024, which is 1855.67% up from last year.
  • Phathom Pharmaceuticals' Other Non-Current Liabilities amounted to $11.5 million in Q3 2025, which was up 697.67% from $11.5 million recorded in Q2 2025.
  • Phathom Pharmaceuticals' Other Non-Current Liabilities' 5-year high stood at $11.5 million during Q4 2024, with a 5-year trough of $7.5 million in Q1 2022.
  • Over the past 4 years, Phathom Pharmaceuticals' median Other Non-Current Liabilities value was $9.7 million (recorded in 2023), while the average stood at $9.3 million.
  • In the last 5 years, Phathom Pharmaceuticals' Other Non-Current Liabilities changed by 0.0% in 2023 and then soared by 4333.33% in 2024.
  • Quarter analysis of 4 years shows Phathom Pharmaceuticals' Other Non-Current Liabilities stood at $7.5 million in 2022, then rose by 29.33% to $9.7 million in 2023, then grew by 18.56% to $11.5 million in 2024, then changed by 0.0% to $11.5 million in 2025.
  • Its last three reported values are $11.5 million in Q3 2025, $11.5 million for Q2 2025, and $11.5 million during Q1 2025.